Log in

NASDAQ:AXDXAccelerate Diagnostics Stock Price, Forecast & News

+0.80 (+5.44 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $15.50
50-Day Range
MA: $15.19
52-Week Range
Now: $15.50
Volume410,857 shs
Average Volume310,700 shs
Market Capitalization$856.69 million
P/E RatioN/A
Dividend YieldN/A
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
Read More
Accelerate Diagnostics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.12 out of 5 stars

Industry, Sector and Symbol

Industry Analytical instruments
Current SymbolNASDAQ:AXDX



Sales & Book Value

Annual Sales$9.30 million
Book Value($0.14) per share


Net Income$-84,310,000.00
Net Margins-845.43%


Market Cap$856.69 million
Next Earnings Date11/5/2020 (Estimated)
+0.80 (+5.44 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AXDX News and Ratings via Email

Sign-up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions

How has Accelerate Diagnostics' stock been impacted by COVID-19 (Coronavirus)?

Accelerate Diagnostics' stock was trading at $10.61 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AXDX stock has increased by 46.1% and is now trading at $15.50.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Accelerate Diagnostics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Accelerate Diagnostics

When is Accelerate Diagnostics' next earnings date?

Accelerate Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Accelerate Diagnostics

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics Inc (NASDAQ:AXDX) announced its earnings results on Thursday, May, 7th. The medical research company reported ($0.39) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.39). The medical research company had revenue of $2.34 million for the quarter, compared to analyst estimates of $2.40 million. Accelerate Diagnostics had a negative net margin of 845.43% and a negative return on equity of 5,681.44%.
View Accelerate Diagnostics' earnings history

What price target have analysts set for AXDX?

4 equities research analysts have issued 1-year price objectives for Accelerate Diagnostics' stock. Their forecasts range from $14.00 to $20.00. On average, they expect Accelerate Diagnostics' stock price to reach $17.25 in the next year. This suggests a possible upside of 11.3% from the stock's current price.
View analysts' price targets for Accelerate Diagnostics

Has Accelerate Diagnostics been receiving favorable news coverage?

Press coverage about AXDX stock has been trending negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Accelerate Diagnostics earned a daily sentiment score of -2.5 on InfoTrie's scale. They also assigned news articles about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about Accelerate Diagnostics

Are investors shorting Accelerate Diagnostics?

Accelerate Diagnostics saw a decrease in short interest in July. As of July 31st, there was short interest totaling 15,760,000 shares, a decrease of 8.9% from the July 15th total of 17,300,000 shares. Based on an average trading volume of 497,200 shares, the days-to-cover ratio is presently 31.7 days. Approximately 56.3% of the shares of the stock are short sold.
View Accelerate Diagnostics' Short Interest

Who are some of Accelerate Diagnostics' key competitors?

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AbbVie (ABBV), AT&T (T) and Exelixis (EXEL).

Who are Accelerate Diagnostics' key executives?

Accelerate Diagnostics' management team includes the following people:
  • Mr. Lawrence Mehren, Pres, CEO, Director and Interim Head of Europe, Middle East & Africa (Age 53)
  • Mr. Steve Reichling, Chief Financial Officer (Age 41)
  • Mr. Ron Price, Sr. VP & Head of Commercial Operations - Americas (Age 55)
  • Mr. Kurt Reinhardt, Head of Operations
  • Dr. Romney M. Humphries, Chief Scientific Officer (Age 38)

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Who are Accelerate Diagnostics' major shareholders?

Accelerate Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Cannell Peter B & Co. Inc. (2.02%), Chicago Capital LLC (1.37%), UBS Group AG (0.15%), Swiss National Bank (0.12%), Mitsubishi UFJ Kokusai Asset Management Co. Ltd. (0.07%) and New York State Common Retirement Fund (0.05%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, John Patience, Romney Humphries, Steven Reichling and Thomas D Brown.
View institutional ownership trends for Accelerate Diagnostics

Which institutional investors are selling Accelerate Diagnostics stock?

AXDX stock was sold by a variety of institutional investors in the last quarter, including Chicago Capital LLC, and UBS Group AG.
View insider buying and selling activity for Accelerate Diagnostics

Which institutional investors are buying Accelerate Diagnostics stock?

AXDX stock was purchased by a variety of institutional investors in the last quarter, including Cannell Peter B & Co. Inc., Russell Investments Group Ltd., Mitsubishi UFJ Kokusai Asset Management Co. Ltd., SG Americas Securities LLC, Principal Financial Group Inc., Virtu Financial LLC, Swiss National Bank, and New York State Common Retirement Fund. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, John Patience, Steven Reichling, and Thomas D Brown.
View insider buying and selling activity for Accelerate Diagnostics

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Accelerate Diagnostics' stock price today?

One share of AXDX stock can currently be purchased for approximately $15.50.

How big of a company is Accelerate Diagnostics?

Accelerate Diagnostics has a market capitalization of $856.69 million and generates $9.30 million in revenue each year. The medical research company earns $-84,310,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. Accelerate Diagnostics employs 287 workers across the globe.

What is Accelerate Diagnostics' official website?

The official website for Accelerate Diagnostics is acceleratediagnostics.com.

How can I contact Accelerate Diagnostics?

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.